razoxane has been researched along with cardiovascular agents in 125 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 61 (48.80) | 18.2507 |
| 2000's | 49 (39.20) | 29.6817 |
| 2010's | 15 (12.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pellizzato, R; Vigevani, A; Zampieri, M | 1 |
| Hochster, H; Speyer, J; Wasserheit, C | 1 |
| Bagdasarov, IuB; Min'kov, ED; Niu-Tian-de, GB; Odzharova, AA; Shkhvatsabaia, LV; Zaĭtseva, TI | 1 |
| Garin, AM; Lichinitser, MR; Min'kov, ED; Nakhalova, TA; Odzharova, AA; Vyshinskaia, GV | 1 |
| Bast, A; Grimbergen, JA; Kramer, K; van Acker, SA; van der Vijgh, WJ; Voest, EE; Zhang, J | 1 |
| Lipshultz, SE | 2 |
| Hellmann, K | 3 |
| Andrich, MP; Avila, N; Balis, FM; Berg, SL; Chen, CC; Dilsizian, V; Horowitz, ME; Jarosinski, P; Poplack, DG; Venzon, D; Weaver-McClure, L; Wexler, LH | 1 |
| Chaloupka, V; Elbl, L; Hájek, R; Vásová, I; Vorlícek, J | 1 |
| Hasinoff, BB; Malisza, KL | 1 |
| Baldwin, JR; Hatfield, NZ; Lewis, RC; Narang, PK; Overmyer, SK; Phillips, BA | 1 |
| Holm, B; Jensen, PB; Sehested, M | 1 |
| Sledge, GW | 1 |
| Clark, JR; Ferrans, VJ; Herman, EH; Zhang, J | 1 |
| Bellina, RC; Bruzzi, P; Carnino, F; Conte, PF; Cyrus, P; Del Mastro, L; Gallo, L; Garrone, O; Guelfi, M; Lionetto, R; Michelotti, A; Molea, N; Pronzato, P; Rosso, R; Testore, F; Tibaldi, C; Venturini, M; Vinke, J | 1 |
| Lemez, P; Maresová, J | 2 |
| Garin, AM; Lichinitser, MP; Min'kov, ED; Nakhalova, TA; Odzharova, AA; Vyshinskaia, GV | 1 |
| Sauer, H | 1 |
| Betcher, DL; O'Marcaigh, AS | 1 |
| Bianchine, JR; Desai, A; Ewer, MS; Gams, RA; Gerber, MC; Jones, SE; Mittelman, A; Pendergrass, K; Reddy, S; Speyer, J; Spicer, D; Swain, SM; Velez-Garcia, E; Vogel, C; Wadler, S; Weisberg, S; Whaley, FS; York, M | 1 |
| Bianchine, JR; Ewer, MS; Gams, RA; Gerber, MC; Swain, SM; Whaley, FS | 1 |
| Grossmann, V; Kvĕtina, J; Safárová, M; Svoboda, Z | 1 |
| Brock, J; Grünewald, K; Kastner, S; Thaler, J; Weiss, G | 1 |
| Chadwick, DP; Clark, JR; Ferrans, VJ; Hasinoff, BB; Herman, EH; Zhang, J | 1 |
| Gavrikova, NV; Gavrilova, IE; Il'iashenko, VV; Ivanova, LF; Kurdiukov, BV; Kurmashov, VI; Maiakova, SA; Morozova, OV; Popa, AV; Terzich, M | 1 |
| Dedukh, VM; Kolygin, BA; Punanov, IuA; Safonova, SA | 1 |
| Blum, RH | 1 |
| Conti, F; Di Lauro, K; Ferraironi, A; Giannarelli, D; Lopez, M; Maini, CL; Paoletti, G; Sciuto, R; Vici, P | 1 |
| Semiglazov, VF | 1 |
| Fattman, CL; Hasinoff, BB; Kuschak, TI; Yalowich, JC | 1 |
| Phillips, KA; Tannock, IF | 1 |
| Hasinoff, BB | 2 |
| Ferrans, VJ; Herman, EH | 1 |
| Imondi, AR | 1 |
| Von Hoff, DD | 1 |
| Hochster, HS | 1 |
| Swain, SM | 2 |
| Lopez, M; Vici, P | 1 |
| Sparano, JA | 1 |
| Wexler, LH | 1 |
| Doroshow, JH; Synold, TW; Tetef, ML | 1 |
| Spencer, CM; Wiseman, LR | 1 |
| Speyer, J; Wasserheit, C | 1 |
| Mazzarello, GP; Morra, L | 1 |
| DiSalle, M; Lifton, R; Woodlock, TJ | 1 |
| Aoyama, RG; Hasinoff, BB | 1 |
| Arstall, MA; Fukazawa, R; Kelly, RA; Sawyer, DB | 1 |
| Muggia, FM; Speyer, JL | 1 |
| Ben-Yehuda, D; Lossos, IS | 1 |
| Kuz'mina, LP; Manikhas, GM; Protasov, DA; Zel'dovich, DR | 1 |
| Allan, WP; Chee, GL; Hasinoff, BB; Thampatty, P; Yalowich, JC | 1 |
| Bramwell, V; Moran, LA; Seymour, L | 1 |
| Broder, G; Cohen, GI; Gradishar, WJ; Green, DM; Hensley, ML; Langdon, RJ; Lindley, C; Meropol, NJ; Mitchell, RB; Negrin, R; Pfister, DG; Schuchter, LM; Szatrowski, TP; Thigpen, JT; Von Hoff, D; Wasserman, TH; Winer, EP | 1 |
| Chen, S; Garami, M; Gardner, DG | 1 |
| Bajgar, J; Cerman, J; Gersl, V; Hrdina, R; Machácková, J; Mazurová, Y; Suba, P | 1 |
| Arnold, P; Diop, NK; Marusak, RA; Shang, M; Vitellaro, LK | 1 |
| Bengala, C; Carnino, F; Conte, P; Del Mastro, L; Gallo, L; Lionetto, R; Michelotti, A; Montanaro, E; Rosso, R; Tibaldi, C; Venturini, M | 1 |
| Buter, J; Giaccone, G; Jensen, PB; Langer, SW; Sehested, M | 1 |
| Kwok, JC; Richardson, DR | 1 |
| Gershanovich, ML | 2 |
| Bernadic, M; Foltinová, A; Hulín, I; Mladosievicova, B; Petrásová, H | 1 |
| Alpert, L; Chalifour, LE; Kirby, GM; Mitmaker, B; Saadane, N; Yue, P | 1 |
| Chadwick, DP; Chai, J; Ferrans, VJ; Hasinoff, BB; Herman, EH; Knapton, A; Lipshultz, SE; Rifai, N; Zhang, J | 1 |
| Ostański, M; Sońta-Jakimczyk, D | 2 |
| Bottone, AE; de Beer, EL; van der Velden, J; van Rijk, MC; Voest, EE | 1 |
| Ferrans, VJ; Hasinoff, BB; Takeda, K; Yu, ZX | 1 |
| Adamkiewicz-Drozyńska, E; Aleszewicz-Baranowska, J; Balcerska, A; Bień, E; Kaczorowska, B; Kowalczyk, J; Kołecki, P; Kurylak, A; Sierota, D; Stachowicz-Stencel, T; Stefanska, K; Szołkiewicz, A | 1 |
| Arundell, E; Bates, M; Lieu, D; Tonkin, K; Williamson, T; Zagari, M | 1 |
| Kolygin, BA | 1 |
| Dimayuga, C; Hudaihed, A; Katz, SD; Zheng, H | 1 |
| Gisterek, I; Mazur, G; Wróbel, T; Włodarska, I; Zymliński, R; Łacko, A | 1 |
| Hasinoff, BB; Schroeder, PE | 1 |
| Komagata, H; Sakai, H | 1 |
| Hasinoff, BB; Huebner, E; Marusak, RA; Patel, D; Schnabl, KL | 1 |
| Al-Khadimi, Z; Chow, WA; Doroshow, JH; Frankel, P; Lawrence, J; Leong, L; Lim, D; Longmate, J; Margolin, K; Morgan, RJ; Raschko, J; Shibata, S; Somlo, G; Synold, TW; Tetef, ML; Twardowski, P; Yen, Y | 1 |
| de Vries, EG; Perik, PJ; van den Berg, MP; van Veldhuisen, DJ | 1 |
| Adamcová, M; Gersl, V; Hrdina, R; Kaplanová, J; Klimtová, I; Mazurová, Y; Simůnek, T; Sterba, M | 1 |
| Caron, HN; Kremer, LC | 1 |
| Asselin, BL; Barr, RD; Clavell, LA; Colan, SD; Dalton, VM; Gelber, RD; Hurwitz, CA; Levy, DE; Lipshultz, SE; Lipsitz, SR; Moghrabi, A; Rifai, N; Sallan, SE; Samson, Y; Schorin, MA; Silverman, LB | 1 |
| Fujisaki, G; Inokuchi, C; Murashige, N | 1 |
| Antoniou, J; Chalifour, LE; Demers, CN; Héon, S; Kirby, GM; Mwale, F; Servant, N; Wang, C | 1 |
| Hasinoff, BB; Wu, X | 1 |
| Anderson, B | 1 |
| Cvetković, RS; Scott, LJ | 1 |
| Hofland, KF; Jensen, PB; Sehested, M; Thougaard, AV | 1 |
| Elbl, L; Hrstkova, H; Michalek, J; Tomaskova, I | 1 |
| Blazek, B; Elbl, L; Hrstkova, H; Michalek, J; Tomaskova, I | 1 |
| Antoniou, J; Chalifour, LE; Ciobanu, I; Demers, CN; Héon, S; Mwale, F; Servant, N | 1 |
| Silber, JH | 1 |
| Carpi, A; Cecconi, N; Cervetti, G; Franzoni, F; Galetta, F; Petrini, M; Santoro, G | 1 |
| Bernitsas, E; Mikol, DD; Wei, W | 1 |
| Chan, WY; Fok, TF; Huang, WZ; Lee, SM; Li, CK; Li, K; Ng, PC; Pong, NH; Sung, RY; To, MY; Wong, YO; Yang, M; Zhao, H | 1 |
| Kik, K; Szmigiero, L | 1 |
| Granger, CB | 1 |
| Csóka, M; Erdélyi, D; Erlaky, H; Horváth, E; Jókúti, L; Kovács, GT; Müller, J; Szabolcs, J; Tóth, K | 1 |
| Alvarez, JA; Barry, E; Lipshultz, SE; Miller, TL; Scully, RE | 1 |
| Geist, A; Haberstroh, J; Ketelsen, UP; Lebrecht, D; Setzer, B; Walker, UA | 1 |
| Hasinoff, BB; Herman, EH | 1 |
| Jensen, PB; Langer, SW; Sehested, M | 1 |
| Bjelogrlic, SK; Jokanovic, M; Jovic, V; Radic, J; Radulovic, S | 1 |
| Bosso, G; Ceste, M; de Conciliis, E; Ferrero, G; Ferro, S; Giaretto, L; Lanfranco, C; Manfredi, R; Miglietta, L; Milanese, S; Parello, G; Simoni, C; Testore, F | 1 |
| Bois, P; Dilly, S; Ducroq, J; Faivre, JF; Guilbot, S; Laemmel, E; Le Grand, M; Moha ou Maati, H; Pons-Himbert, C; Stücker, O | 1 |
| Gallegos-Castorena, S; Gonzalez-Ramella, O; Sánchez-Medina, J | 1 |
| Adamcová, M; Aupperle, H; Geršl, V; Mazurová, Y; Popelová, O; Potáčová, A; Štěrba, M | 1 |
| Aronoff, GR; Brier, ME; Fang, A; Gaylor, SK; Glue, P; McGovren, JP | 1 |
| Beijnen, JH; Goey, AK; Huitema, AD; Schellens, JH | 1 |
| Ahn, HS; Choi, HS; Choi, JY; Kang, HJ; Noh, CI; Park, ES; Shin, HY; Yun, YS | 1 |
| Asselin, BL; Athale, U; Barry, EV; Clavell, LA; Cohen, HJ; Colan, SD; Larsen, E; Lipshultz, SE; Lipsitz, SR; Michon, B; Miller, TL; Moghrabi, A; Neuberg, DS; Orav, EJ; Sallan, SE; Samson, Y; Schorin, MA; Scully, RE; Silverman, LB | 1 |
| Dervisis, NG; FitzPatrick, WM; Kitchell, BE | 1 |
| Hrušková, K; Klimeš, J; Kovaříková, P; Stariat, J; Vávrová, K | 1 |
| McBride, D | 1 |
| Boudíková, A; Dabrowská, L; Geršl, V; Kolář, F; Mandíková, P; Mikšík, I; Mráz, J; Neckář, J; Popelová, O; Stěrba, M | 1 |
| Kang, M; Kim, KI; Oh, JM; Shin, WG; Song, YC | 1 |
| Klimes, J; Kovarikova, P; Pasakova-Vrbatova, I; Simunek, T; Stariat, J; Vavrova, A | 1 |
| Brandt, A; Ebner, A; Ebner, B; Forkmann, M; Hofmann, A; Morawietz, H; Polanski, AK; Steinbronn, N; Strasser, RH; Tausche, AK; Wunderlich, C | 1 |
| Hao, XM; Li, WJ; Wang, P; Zhang, J; Zhang, S; Zhang, XB | 1 |
29 review(s) available for razoxane and cardiovascular agents
| Article | Year |
|---|---|
Cardiotoxicity and cardioprotection during chemotherapy.
Topics: Adult; Anthracyclines; Antineoplastic Agents; Cardiovascular Agents; Child; Clinical Trials as Topic; Cyclophosphamide; Female; Fluorouracil; Heart; Heart Diseases; Humans; Interleukin-2; Male; Neoplasms; Paclitaxel; Razoxane; Retrospective Studies; Survivors | 1995 |
Cardioprotection by dexrazoxane (Cardioxane; ICRF 187): progress in supportive care.
Topics: Adult; Antibiotics, Antineoplastic; Cardiomyopathies; Cardiovascular Agents; Child; Child, Preschool; Clinical Trials as Topic; Dose-Response Relationship, Drug; Doxorubicin; Female; Humans; Male; Neoplasms; Razoxane; Treatment Outcome | 1996 |
Dexrazoxane (ICRF-187): a cardioprotective agent during anthracycline chemotherapy.
Topics: Antibiotics, Antineoplastic; Cardiovascular Agents; Heart Diseases; Humans; Razoxane | 1997 |
Clinical status and optimal use of the cardioprotectant, dexrazoxane.
Topics: Antibiotics, Antineoplastic; Breast Neoplasms; Cardiovascular Agents; Clinical Trials as Topic; Combined Modality Therapy; Dose-Response Relationship, Drug; Doxorubicin; Female; Heart; Heart Diseases; Humans; Iron; Myocardium; Razoxane; Safety; Treatment Outcome | 1997 |
[Preventing the cardiotoxic effects of anthracyclines with Cardioxane].
Topics: Antibiotics, Antineoplastic; Cardiovascular Agents; Heart; Heart Diseases; Humans; Razoxane | 1997 |
Design and interpretation of clinical trials that evaluate agents that may offer protection from the toxic effects of cancer chemotherapy.
Topics: Amifostine; Antineoplastic Agents; Cardiovascular Agents; Clinical Trials, Phase III as Topic; Heart Diseases; Hematopoietic Cell Growth Factors; Humans; Leukopoiesis; Randomized Controlled Trials as Topic; Razoxane; Research Design; Thrombocytopenia | 1998 |
Preclinical animal models of cardiac protection from anthracycline-induced cardiotoxicity.
Topics: Animals; Anthracyclines; Antineoplastic Agents; Cardiomyopathies; Cardiovascular Agents; Disease Models, Animal; Dogs; Heart; Mice; Rabbits; Rats; Razoxane; Swine | 1998 |
Preclinical models of cardiac protection and testing for effects of dexrazoxane on doxorubicin antitumor effects.
Topics: Animals; Antineoplastic Agents; Cardiovascular Agents; Dogs; Dose-Response Relationship, Drug; Doxorubicin; Evaluation Studies as Topic; Heart; Humans; Mice; Neoplasms, Experimental; Rabbits; Rats; Razoxane; Swine | 1998 |
Phase I trials of dexrazoxane and other potential applications for the agent.
Topics: Antineoplastic Agents; Cardiovascular Agents; Chelating Agents; Clinical Trials, Phase I as Topic; Humans; Razoxane; Topoisomerase II Inhibitors | 1998 |
Clinical pharmacology of dexrazoxane.
Topics: Animals; Anthracyclines; Antineoplastic Agents; Cardiovascular Agents; Clinical Trials as Topic; Evaluation Studies as Topic; Humans; Iron Chelating Agents; Razoxane | 1998 |
Adult multicenter trials using dexrazoxane to protect against cardiac toxicity.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiovascular Agents; Dose-Response Relationship, Drug; Doxorubicin; Female; Heart Diseases; Humans; Multicenter Studies as Topic; Neoplasm Metastasis; Randomized Controlled Trials as Topic; Razoxane | 1998 |
Overview and historical development of dexrazoxane.
Topics: Adult; Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Cardiovascular Agents; Child; Clinical Trials as Topic; Heart Diseases; Humans; Razoxane | 1998 |
European trials with dexrazoxane in amelioration of doxorubicin and epirubicin-induced cardiotoxicity.
Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Agents; Clinical Trials as Topic; Doxorubicin; Epirubicin; Europe; Heart Diseases; Humans; Razoxane | 1998 |
Use of dexrazoxane and other strategies to prevent cardiomyopathy associated with doxorubicin-taxane combinations.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cardiomyopathies; Cardiovascular Agents; Clinical Trials as Topic; Doxorubicin; Drug Administration Schedule; Humans; Paclitaxel; Razoxane | 1998 |
Ameliorating anthracycline cardiotoxicity in children with cancer: clinical trials with dexrazoxane.
Topics: Anthracyclines; Antineoplastic Agents; Cardiovascular Agents; Child; Clinical Trials as Topic; Heart Diseases; Humans; Razoxane | 1998 |
Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Cardiovascular Agents; Chelating Agents; Heart Diseases; Humans; Neoplasms; Razoxane | 1998 |
Strategies for reduction of anthracycline cardiac toxicity.
Topics: Adult; Animals; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cardiomyopathies; Cardiovascular Agents; Chelating Agents; Child; Clinical Trials as Topic; Diagnostic Imaging; Humans; Liposomes; Razoxane | 1998 |
[Anthracyclines and the heart].
Topics: Anthracyclines; Cardiovascular Agents; Heart; Heart Diseases; Humans; Razoxane | 1998 |
The cardioprotective effect of the iron chelator dexrazoxane (ICRF-187) on anthracycline-mediated cardiotoxicity.
Topics: Animals; Anthracyclines; Antineoplastic Agents; Cardiovascular Agents; Chelating Agents; Heart; Humans; Razoxane | 2000 |
[Cardiac toxicity in cancer therapy].
Topics: Antibiotics, Antineoplastic; Breast Neoplasms; Cardiomyopathy, Dilated; Cardiovascular Agents; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Female; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Neoplasms; Radiotherapy, Adjuvant; Razoxane; Risk Factors; Sarcoma | 2002 |
[Chemotherapy-induced cardiac toxicity and management].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Agents; Dose-Response Relationship, Drug; Doxorubicin; Echocardiography; Heart; Heart Diseases; Humans; Monitoring, Physiologic; Neoplasms; Razoxane | 2003 |
Dexrazoxane for the prevention of cardiomyopathy in anthracycline treated pediatric cancer patients.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Cardiomyopathies; Cardiovascular Agents; Child; Humans; Neoplasms; Razoxane | 2005 |
Dexrazoxane : a review of its use for cardioprotection during anthracycline chemotherapy.
Topics: Anthracyclines; Antineoplastic Agents; Cardiovascular Agents; Cardiovascular Diseases; Humans; Neoplasms; Randomized Controlled Trials as Topic; Razoxane | 2005 |
Exposure to anthracyclines during childhood causes cardiac injury.
Topics: Adolescent; Adult; Anthracyclines; Antineoplastic Agents; Cardiomyopathies; Cardiovascular Agents; Child; Disease Progression; Heart; Heart Failure; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Razoxane; Risk Factors; Survivors | 2006 |
[Dexrazoxane (ICRF-187)--a cardioprotectant and modulator of action of some anticancer drugs].
Topics: Anthracyclines; Antibiotics, Antineoplastic; Cardiomyopathies; Cardiovascular Agents; Chelating Agents; Neoplasms; Razoxane | 2006 |
Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Cardiovascular Agents; Drug Interactions; Drug Monitoring; Heart; Heart Diseases; Humans; Neoplasms; Razoxane; Risk Factors | 2007 |
Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug?
Topics: Animals; Antineoplastic Agents; Cardiovascular Agents; Clinical Trials as Topic; Doxorubicin; Enzyme Inhibitors; Heart Diseases; Humans; Neoplasms; Prodrugs; Razoxane; Topoisomerase II Inhibitors | 2007 |
Other uses of dexrazoxane: Savene, the first proven antidote against anthracycline extravasation injuries.
Topics: Animals; Anthracyclines; Antibiotics, Antineoplastic; Cardiovascular Agents; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Heart Diseases; Humans; Mice; Razoxane | 2007 |
[Dexrazoxane in anthracycline induced cardiotoxicity and extravasation].
Topics: Anthracyclines; Cardiovascular Agents; Heart Diseases; Heart Failure; Humans; Randomized Controlled Trials as Topic; Razoxane | 2010 |
23 trial(s) available for razoxane and cardiovascular agents
| Article | Year |
|---|---|
[An evaluation of the cardioprotective action of the preparation ICRF-187 (Cardioxane) during the treatment of breast cancer with large doses of adriamycin].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiomyopathies; Cardiovascular Agents; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Heart; Humans; Middle Aged; Myocardial Contraction; Razoxane; Time Factors | 1994 |
Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Cardiovascular Agents; Child; Doxorubicin; Female; Heart; Humans; Injections, Intravenous; Male; Neuroectodermal Tumors, Primitive, Peripheral; Razoxane; Rhabdomyosarcoma; Sarcoma; Sarcoma, Ewing; Soft Tissue Neoplasms; Stroke Volume; Survival Rate; Transaminases | 1996 |
Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiovascular Agents; Epirubicin; Female; Heart Diseases; Humans; Middle Aged; Razoxane | 1996 |
Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiovascular Agents; Cyclophosphamide; Disease-Free Survival; Double-Blind Method; Doxorubicin; Female; Fluorouracil; Heart Failure; Humans; Prospective Studies; Razoxane; Risk Factors; Survival Analysis; Treatment Outcome | 1997 |
Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiovascular Agents; Cyclophosphamide; Disease-Free Survival; Double-Blind Method; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Heart Failure; Humans; Middle Aged; Prospective Studies; Razoxane; Treatment Outcome | 1997 |
Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Breast Neoplasms; Cardiovascular Agents; Drug Monitoring; Epirubicin; Female; Heart; Heart Rate; Humans; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Radionuclide Imaging; Razoxane; Sarcoma; Ventricular Function, Left | 1998 |
Efficacy of dexrazoxane as a cardioprotective agent in patients receiving mitoxantrone- and daunorubicin-based chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Agents; Daunorubicin; Female; Heart Diseases; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Razoxane | 1998 |
Antineoplastic activity of continuous exposure to dexrazoxane: potential new role as a novel topoisomerase II inhibitor.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Agents; Doxorubicin; Heart Diseases; Humans; Razoxane; Topoisomerase II Inhibitors | 1998 |
[The role of cardioxane (ICRF-187) in the prevention of cardiotoxicity of anthracyclines in the combined drug therapy of extensive ovarian cancer].
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Agents; Doxorubicin; Female; Heart; Humans; Ovarian Neoplasms; Razoxane; Treatment Outcome | 1998 |
Single agent epirubicin as first line chemotherapy for metastatic breast cancer patients.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Breast Neoplasms; Cardiovascular Agents; Epirubicin; Female; Heart Failure; Humans; Injections, Intravenous; Middle Aged; Razoxane; Treatment Outcome; Ventricular Dysfunction, Left | 2000 |
Signal-averaged electrocardiography in survivors of Hodgkin's disease treated with and without dexrazoxane.
Topics: Adolescent; Antineoplastic Agents; Arrhythmias, Cardiac; Cardiomyopathies; Cardiovascular Agents; Child; Child, Preschool; Combined Modality Therapy; Doxorubicin; Electrocardiography; Female; Fourier Analysis; Hodgkin Disease; Humans; Infant; Male; Razoxane | 2001 |
Dexrazoxane cardioprotection for patients receiving FAC chemotherapy: a pharmacoeconomic evaluation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiovascular Agents; Cost-Benefit Analysis; Cyclophosphamide; Decision Support Techniques; Doxorubicin; Economics, Pharmaceutical; Female; Fluorouracil; Health Care Costs; Heart; Heart Diseases; Humans; Markov Chains; Middle Aged; Models, Economic; Neoplasm Staging; Razoxane; Sensitivity and Specificity | 1996 |
Effect of dexrazoxane on homocysteine-induced endothelial dysfunction in normal subjects.
Topics: Adult; Antioxidants; Blood Flow Velocity; Brachial Artery; Cardiovascular Agents; Chelating Agents; Cross-Over Studies; Endothelium, Vascular; Female; Homocysteine; Humans; Iron; Male; Methionine; Oxidative Stress; Razoxane | 2002 |
Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignancies.
Topics: Adult; Antibiotics, Antineoplastic; Cardiovascular Agents; Doxorubicin; Drug Administration Schedule; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Factor; Heart Failure; Humans; Infusions, Intravenous; Levofloxacin; Male; Middle Aged; Neoplasms; Neutropenia; Ofloxacin; Razoxane; Sarcoma; Sepsis; Treatment Outcome | 2004 |
The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia.
Topics: Antibiotics, Antineoplastic; Cardiomyopathies; Cardiovascular Agents; Chelating Agents; Child; Disease-Free Survival; Doxorubicin; Echocardiography; Female; Heart; Humans; Logistic Models; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Razoxane; Troponin T; Ventricular Function, Left | 2004 |
Late anthracycline cardiotoxicity protection by dexrazoxane (ICRF-187) in pediatric patients: echocardiographic follow-up.
Topics: Adolescent; Adult; Anthracyclines; Antibiotics, Antineoplastic; Cardiomyopathies; Cardiovascular Agents; Child; Child, Preschool; Echocardiography; Female; Follow-Up Studies; Heart Failure; Hematologic Neoplasms; Humans; Male; Razoxane; Retrospective Studies; Stroke Volume; Survival Analysis; Treatment Outcome | 2006 |
Long-term serial echocardiographic examination of late anthracycline cardiotoxicity and its prevention by dexrazoxane in paediatric patients.
Topics: Adolescent; Anthracyclines; Antineoplastic Agents; Blood Pressure; Body Mass Index; Cardiovascular Agents; Child; Child, Preschool; Czech Republic; Daunorubicin; Dose-Response Relationship, Drug; Doxorubicin; Echocardiography, Stress; Female; Follow-Up Studies; Heart; Heart Rate; Humans; Infant; Male; Neoplasms; Prospective Studies; Razoxane; Time Factors; Treatment Outcome | 2005 |
Effect of epirubicin-based chemotherapy and dexrazoxane supplementation on QT dispersion in non-Hodgkin lymphoma patients.
Topics: Antibiotics, Antineoplastic; Arrhythmias, Cardiac; Cardiovascular Agents; Drug Therapy, Combination; Electrocardiography; Epirubicin; Female; Heart Conduction System; Humans; Lymphoma, Non-Hodgkin; Male; Razoxane; Time Factors | 2005 |
Suppression of mitoxantrone cardiotoxicity in multiple sclerosis patients by dexrazoxane.
Topics: Adult; Animals; Antineoplastic Agents; Cardiovascular Agents; Female; Heart Failure; Humans; Male; Middle Aged; Mitoxantrone; Multiple Sclerosis; Razoxane; Stroke Volume; Troponin I | 2006 |
Pharmacokinetics of dexrazoxane in subjects with impaired kidney function.
Topics: Adult; Aged; Area Under Curve; Body Surface Area; Cardiovascular Agents; Chromatography, High Pressure Liquid; Creatinine; Female; Half-Life; Humans; Infusions, Intravenous; Kentucky; Kidney; Linear Models; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Nonlinear Dynamics; Razoxane; Renal Insufficiency; Tandem Mass Spectrometry; Young Adult | 2011 |
Dexrazoxane for preventing anthracycline cardiotoxicity in children with solid tumors.
Topics: Adolescent; Antibiotics, Antineoplastic; Cardiomyopathies; Cardiovascular Agents; Child; Child, Preschool; Cohort Studies; Disease-Free Survival; Doxorubicin; Echocardiography; Female; Follow-Up Studies; Heart Failure; Humans; Infant; Male; Neoplasms; Razoxane; Ventricular Function, Left | 2010 |
Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial.
Topics: Adolescent; Antibiotics, Antineoplastic; Biomarkers; Canada; Cardiomyopathies; Cardiovascular Agents; Child; Child, Preschool; Disease-Free Survival; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Male; Myocardial Contraction; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Puerto Rico; Razoxane; Risk Assessment; Risk Factors; Survivors; Time Factors; Treatment Outcome; Troponin T; Ultrasonography; United States; Ventricular Function, Left; Young Adult | 2010 |
[Protective effect of dexrazoxane on cardiotoxicity in breast cancer patients who received anthracycline-containing chemotherapy].
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Bone Marrow; Breast Neoplasms; Cardiovascular Agents; Chemotherapy, Adjuvant; Epirubicin; Female; Follow-Up Studies; Heart Rate; Humans; Leukocyte Count; Middle Aged; Natriuretic Peptide, Brain; Neutrophils; Razoxane; Stroke Volume; Young Adult | 2013 |
73 other study(ies) available for razoxane and cardiovascular agents
| Article | Year |
|---|---|
Thermal behaviour and binary phase diagram of (S)-(+)-4,4'-(1-methyl-1,2-ethandiyl)-bis-(2,6-piperazinedione) (dexrazoxane), a cardioprotective agent, and of its (R)-(-)-enantiomer.
Topics: Algorithms; Calorimetry, Differential Scanning; Cardiovascular Agents; Razoxane; Stereoisomerism; Temperature | 1992 |
[The use of Cardioxan as a cardioprotective agent during antitumor chemotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiomyopathies; Cardiovascular Agents; Cyclophosphamide; Doxorubicin; Drug Evaluation; Drug Interactions; Female; Fluorouracil; Heart; Humans; Middle Aged; Razoxane; Remission Induction | 1994 |
New drug counters doxorubicin cardiotoxicity; not for use at start of chemotherapy.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiovascular Agents; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Heart; Heart Failure; Humans; Razoxane | 1995 |
Doxorubicin-induced cardiotoxicity monitored by ECG in freely moving mice. A new model to test potential protectors.
Topics: Analysis of Variance; Animals; Antineoplastic Agents, Alkylating; Behavior, Animal; Body Weight; Cardiomyopathies; Cardiovascular Agents; Doxorubicin; Drug Interactions; Electrocardiography; Heart; Heart Atria; Heart Rate; Injections, Intraperitoneal; Injections, Intravenous; Male; Mice; Mice, Inbred BALB C; Razoxane; Telemetry | 1996 |
Dexrazoxane for protection against cardiotoxic effects of anthracyclines in children.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Cardiovascular Agents; Child; Heart; Heart Diseases; Humans; Neoplasms; Razoxane | 1996 |
Anthracycline cardiotoxicity prevention by dexrazoxane: breakthrough of a barrier--sharpens antitumor profile and therapeutic index.
Topics: Adult; Animals; Antibiotics, Antineoplastic; Cardiovascular Agents; Child; Heart; Heart Diseases; Humans; Neoplasms; Razoxane | 1996 |
[Evaluation of the cardioprotective effect of bispiperazinedione ICRF-187 (Cardioxane) in patients treated with anthracyclines--an echocardiographic study].
Topics: Adult; Antibiotics, Antineoplastic; Cardiovascular Agents; Doxorubicin; Echocardiography; Female; Heart; Humans; Male; Razoxane; Ventricular Function, Left | 1996 |
Inhibition of anthracycline semiquinone formation by ICRF-187 (dexrazoxane) in cells.
Topics: Animals; Antibiotics, Antineoplastic; Cardiovascular Agents; Cell Survival; CHO Cells; Cricetinae; Drug Evaluation, Preclinical; Electron Spin Resonance Spectroscopy; Free Radicals; Molecular Structure; Quinones; Razoxane; Spectrometry, Fluorescence | 1996 |
Dose-independent pharmacokinetics of the cardioprotective agent dexrazoxane in dogs.
Topics: Animals; Area Under Curve; Blood Proteins; Cardiovascular Agents; Chromatography, High Pressure Liquid; Dogs; Dose-Response Relationship, Drug; Electrochemistry; Half-Life; Injections, Intravenous; Male; Protein Binding; Razoxane | 1996 |
Dexrazoxane for protection against cardiotoxic effects of anthracyclines.
Topics: Antibiotics, Antineoplastic; Cardiovascular Agents; DNA Topoisomerases, Type II; Humans; Razoxane | 1996 |
Paclitaxel doublets in metastatic breast cancer: Eastern Cooperative Oncology Group and Hoosier Oncology Group Studies.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiovascular Agents; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Doxorubicin; Female; Heart; Humans; Multicenter Studies as Topic; Neoplasm Metastasis; Paclitaxel; Pilot Projects; Prospective Studies; Randomized Controlled Trials as Topic; Razoxane | 1996 |
Doxorubicin-induced apoptosis in spontaneously hypertensive rats: differential effects in heart, kidney and intestine, and inhibition by ICRF-187.
Topics: Animals; Apoptosis; Cardiomyopathies; Cardiovascular Agents; Dose-Response Relationship, Drug; Doxorubicin; Heart; Hypertension; Immunohistochemistry; Intestines; Iron Chelating Agents; Kidney; Kidney Diseases; Male; Microscopy, Electron; Myocardium; Rats; Rats, Inbred SHR; Razoxane | 1996 |
Protective effects of cardioxane against anthracycline-induced cardiotoxicity in relapsed acute myeloid leukemias.
Topics: Acute Disease; Antibiotics, Antineoplastic; Antineoplastic Agents; Cardiovascular Agents; Cytarabine; Daunorubicin; Female; Heart; Humans; Leukemia, Myeloid; Male; Middle Aged; Razoxane; Recurrence | 1996 |
[Cardioxan as a cardioprotector in antineoplastic chemotherapy].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiovascular Agents; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Heart; Heart Failure; Humans; Radionuclide Ventriculography; Razoxane; Treatment Outcome | 1996 |
[The prevention of anthracycline-induced cardiomyopathy with a chelating agent (dexrazoxane = ICRF-187)].
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Cardiomyopathies; Cardiovascular Agents; Chelating Agents; Humans; Randomized Controlled Trials as Topic; Razoxane | 1997 |
Preclinical comparison of bis-diketopiperazine-propane (dexrazoxane) and bis-diketopiperazine-ethane (antimet) on the adriamycin-cardiotoxic effect.
Topics: Administration, Oral; Animals; Cardiovascular Agents; Doxorubicin; Drug Evaluation, Preclinical; Electroencephalography; Female; Heart Diseases; Myometrium; Piperazines; Rats; Rats, Wistar; Razoxane | 1997 |
Modulation of transferrin receptor expression by dexrazoxane (ICRF-187) via activation of iron regulatory protein.
Topics: Antineoplastic Agents; Cardiovascular Agents; Dose-Response Relationship, Drug; Humans; Iron; Iron-Regulatory Proteins; Iron-Sulfur Proteins; Macrophages; Protein Processing, Post-Translational; Razoxane; Receptors, Transferrin; RNA-Binding Proteins; RNA, Messenger; Tumor Cells, Cultured; Up-Regulation | 1997 |
Comparison of the protective effects against chronic doxorubicin cardiotoxicity and the rates of iron (III) displacement reactions of ICRF-187 and other bisdiketopiperazines.
Topics: Animals; Antibiotics, Antineoplastic; Cardiovascular Agents; Chelating Agents; Diketopiperazines; DNA Topoisomerases, Type II; Doxorubicin; Ethylenediamines; Glycine; Heart; Hydrolysis; Iron; Male; Myocardium; Piperazines; Rats; Rats, Inbred SHR; Razoxane | 1997 |
[Cardioxane in pediatric oncohematology].
Topics: Adolescent; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Agents; Child; Child, Preschool; Drug Administration Schedule; Heart; Humans; Razoxane; Treatment Outcome | 1997 |
[The use of Cardioxane in chemotherapy of malignant neoplasms in children].
Topics: Adolescent; Antibiotics, Antineoplastic; Cardiomyopathies; Cardiovascular Agents; Child; Child, Preschool; Female; Humans; Male; Razoxane; Treatment Outcome | 1997 |
The one-ring open hydrolysis intermediates of the cardioprotective agent dexrazoxane (ICRF-187) do not inhibit the growth of Chinese hamster ovary cells or the catalytic activity of DNA topoisomerase II.
Topics: Animals; Cardiovascular Agents; Catalysis; Cell Division; CHO Cells; Chromatography, High Pressure Liquid; Cricetinae; DNA Topoisomerases, Type II; DNA, Superhelical; Hydrolysis; Razoxane; Topoisomerase II Inhibitors | 1998 |
Chemistry of dexrazoxane and analogues.
Topics: Anthracyclines; Antineoplastic Agents; Cardiovascular Agents; Chromatography, High Pressure Liquid; Copper; Free Radicals; Hydrolysis; Iron; Iron Chelating Agents; Molecular Structure; Protein Binding; Razoxane | 1998 |
Coincident acute myelogenous leukemia and ischemic heart disease: use of the cardioprotectant dexrazoxane during induction chemotherapy.
Topics: Adult; Aged; Cardiovascular Agents; Humans; Leukemia, Myeloid, Acute; Male; Myocardial Ischemia; Razoxane | 1998 |
Relative plasma levels of the cardioprotective drug dexrazoxane and its two active ring-opened metabolites in the rat.
Topics: Animals; Biotransformation; Cardiovascular Agents; Chromatography, High Pressure Liquid; Half-Life; Injections, Intravenous; Male; Rats; Rats, Sprague-Dawley; Razoxane | 1999 |
Daunorubicin-induced apoptosis in rat cardiac myocytes is inhibited by dexrazoxane.
Topics: Animals; Antibiotics, Antineoplastic; Apoptosis; Cardiovascular Agents; Cells, Cultured; Daunorubicin; Dose-Response Relationship, Drug; Heart; Necrosis; Oxidative Stress; Rats; Rats, Sprague-Dawley; Razoxane; Superoxides | 1999 |
Doxorubicin-induced cardiomyopathy.
Topics: Antibiotics, Antineoplastic; Breast Neoplasms; Cardiovascular Agents; Doxorubicin; Heart Failure; Humans; Razoxane | 1999 |
Doxorubicin-induced cardiomyopathy.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cardiomyopathies; Cardiovascular Agents; Doxorubicin; Humans; Razoxane | 1999 |
Cutaneous and subcutaneous necrosis following dexrazoxane-CHOP therapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Agents; Cyclophosphamide; Doxorubicin; Fatal Outcome; Female; Humans; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Necrosis; Prednisone; Razoxane; Skin; Vincristine | 1999 |
The cardioprotective and DNA topoisomerase II inhibitory agent dexrazoxane (ICRF-187) antagonizes camptothecin-mediated growth inhibition of Chinese hamster ovary cells by inhibition of DNA synthesis.
Topics: Animals; Camptothecin; Cardiovascular Agents; Cell Division; CHO Cells; Cricetinae; DNA; Dose-Response Relationship, Drug; Enzyme Inhibitors; Nucleic Acid Synthesis Inhibitors; Razoxane; Time Factors; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 1999 |
Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Cardiovascular Agents; Clinical Trials as Topic; Doxorubicin; Drug Administration Schedule; Epirubicin; Evidence-Based Medicine; Female; Heart; Heart Failure; Humans; Neoplasms; Odds Ratio; Randomized Controlled Trials as Topic; Razoxane; Time Factors; Treatment Outcome | 1999 |
American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants.
Topics: Adult; Amifostine; Antineoplastic Agents; Cardiovascular Agents; Humans; Mesna; Neoplasms; Protective Agents; Radiation-Protective Agents; Radiotherapy; Razoxane | 1999 |
Doxorubicin selectively inhibits brain versus atrial natriuretic peptide gene expression in cultured neonatal rat myocytes.
Topics: Animals; Anticholesteremic Agents; Antineoplastic Agents; Atrial Natriuretic Factor; Cardiovascular Agents; Cell Survival; Cells, Cultured; Dactinomycin; Dose-Response Relationship, Drug; Doxorubicin; Gene Expression; Heart Atria; Natriuretic Peptide, Brain; Probucol; Promoter Regions, Genetic; Protein Synthesis Inhibitors; Rats; Razoxane; RNA, Messenger; Transfection | 1999 |
Cholinesterases in dexrazoxane-treated daunorubicin cardiomyopathy in rabbits.
Topics: Acetylcholinesterase; Animals; Antibiotics, Antineoplastic; Body Weight; Butyrylcholinesterase; Cardiomyopathies; Cardiovascular Agents; Daunorubicin; Heart; Male; Myocardium; Rabbits; Razoxane; Ventricular Function, Left | 1999 |
Iron complexes of the cardioprotective agent dexrazoxane (ICRF-187) and its desmethyl derivative, ICRF-154: solid state structure, solution thermodynamics, and DNA cleavage activity.
Topics: Cardiovascular Agents; Crystallography, X-Ray; DNA; Hydrolysis; Iron; Magnetic Resonance Spectroscopy; Molecular Structure; Razoxane; Solutions; Thermodynamics | 2000 |
Dexrazoxane in anthracycline extravasation.
Topics: Animals; Anthracyclines; Antineoplastic Agents; Cardiovascular Agents; Extravasation of Diagnostic and Therapeutic Materials; Humans; Necrosis; Razoxane | 2000 |
[Cardiotoxicity of antineoplastic anthracycline antibiotics and prevention by cardioxane (Dexrazoxane) in clinical practice].
Topics: Antibiotics, Antineoplastic; Cardiovascular Agents; Heart Conduction System; Heart Diseases; Humans; Razoxane | 2001 |
Diminished molecular response to doxorubicin and loss of cardioprotective effect of dexrazoxane in Egr-1 deficient female mice.
Topics: Animals; Antibiotics, Antineoplastic; Cardiovascular Agents; DNA; DNA-Binding Proteins; Doxorubicin; Early Growth Response Protein 1; Etoposide; Female; Gene Expression Regulation; Immediate-Early Proteins; Mice; Phenotype; Razoxane; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transcription Factors | 2001 |
The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin- and mitoxantrone-induced cardiotoxicity.
Topics: Animals; Antineoplastic Agents; Biomarkers; Cardiovascular Agents; Doxorubicin; Heart; Infusions, Intravenous; Male; Mitoxantrone; Myocardium; Rats; Rats, Inbred SHR; Razoxane; Troponin T | 2001 |
[Exercise tolerance in patients after acute lymphoblastic leukemia treatment in childhood].
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Cardiovascular Agents; Case-Control Studies; Child; Electrocardiography; Exercise Test; Exercise Tolerance; Female; Heart; Humans; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Razoxane; Time Factors | 2001 |
Dexrazoxane pre-treatment protects skinned rat cardiac trabeculae against delayed doxorubicin-induced impairment of crossbridge kinetics.
Topics: Animals; Calcium; Cardiovascular Agents; Doxorubicin; Heart; Kinetics; Male; Muscle Contraction; Myosin Heavy Chains; Protective Agents; Protein Isoforms; Rats; Rats, Wistar; Razoxane | 2002 |
The doxorubicin cardioprotective agent dexrazoxane (ICRF-187) induces endopolyploidy in rat neonatal myocytes through inhibition of DNA topoisomerase II.
Topics: Animals; Animals, Newborn; Antineoplastic Agents; Cardiovascular Agents; Cell Cycle; Cell Division; DNA; Dose-Response Relationship, Drug; Doxorubicin; Heart Ventricles; Microscopy, Confocal; Myocardium; Polyploidy; Rats; Rats, Sprague-Dawley; Razoxane; Topoisomerase II Inhibitors | 2002 |
[Cardiotoxic complications in Wilms' tumour survivors after treatment with anthracyclines].
Topics: Adolescent; Antibiotics, Antineoplastic; Cardiovascular Agents; Child; Child, Preschool; Drug Therapy, Combination; Echocardiography; Female; Heart; Humans; Infant; Kidney Neoplasms; Male; Razoxane; Retrospective Studies; Survival Analysis; Time Factors; Treatment Outcome; Wilms Tumor | 2000 |
[Cardioxan--a drug of prevention of anthracycline-related cardiotoxicity in pediatric oncology].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Cardiomyopathies; Cardiovascular Agents; Child; Child, Preschool; Humans; Razoxane | 2002 |
[Echocardiographic assessment of circulation system in patients during and 3-5 years after all therapy in childhood].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Agents; Case-Control Studies; Child; Child, Preschool; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Echocardiography; Female; Heart Diseases; Humans; Infant; Male; Paclitaxel; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Razoxane; Taxoids; Time Factors; Ventricular Function, Left; Ventricular Function, Right | 2002 |
Dexrazoxane (ICRF-187) protects cardiac myocytes against hypoxia-reoxygenation damage.
Topics: Animals; Cardiovascular Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Ethylenediamines; Extracorporeal Membrane Oxygenation; Fluoresceins; Fluorescent Dyes; Glycine; Hypoxia; Ion Transport; L-Lactate Dehydrogenase; Models, Cardiovascular; Myocytes, Cardiac; Rats; Rats, Sprague-Dawley; Razoxane; Time Factors; Treatment Failure | 2002 |
The doxorubicin-cardioprotective drug dexrazoxane undergoes metabolism in the rat to its metal ion-chelating form ADR-925.
Topics: Animals; Biotransformation; Cardiovascular Agents; Chelating Agents; Chromatography, High Pressure Liquid; Ethylenediamines; Fluoresceins; Glycine; Half-Life; Indicators and Reagents; Infusions, Intravenous; Iron; Male; Molecular Structure; Rats; Rats, Sprague-Dawley; Razoxane | 2002 |
Dexrazoxane (ICRF-187) protects cardiac myocytes against doxorubicin by preventing damage to mitochondria.
Topics: Animals; Animals, Newborn; Apoptosis; Cardiovascular Agents; Cells, Cultured; Dose-Response Relationship, Drug; Doxorubicin; Drug Interactions; Heart Ventricles; Image Processing, Computer-Assisted; Indicators and Reagents; Intracellular Membranes; Membrane Potentials; Mitochondria, Heart; Myocytes, Cardiac; Necrosis; Rats; Rats, Sprague-Dawley; Razoxane; Reactive Oxygen Species | 2003 |
Experimental animal model for anthracycline-induced heart failure.
Topics: Animals; Anthracyclines; Body Weight; Cardiovascular Agents; Disease Models, Animal; Heart Failure; Heart Rate; Models, Cardiovascular; Razoxane; Stroke Volume | 2004 |
Rabbit model for in vivo study of anthracycline-induced heart failure and for the evaluation of protective agents.
Topics: Animals; Anthracyclines; Antibiotics, Antineoplastic; Biomarkers; Body Weight; Cardiovascular Agents; Daunorubicin; Disease Models, Animal; Dose-Response Relationship, Drug; Echocardiography; Erythrocyte Indices; Heart Failure; Heart Rate; Heart Ventricles; Male; Models, Cardiovascular; Myocardium; Myocytes, Cardiac; Rabbits; Razoxane; Stroke Volume; Time Factors | 2004 |
Anthracycline cardiotoxicity in children.
Topics: Anthracyclines; Cardiomyopathies; Cardiovascular Agents; Chelating Agents; Child; Heart; Humans; Predictive Value of Tests; Razoxane; Risk Factors; Troponin T | 2004 |
Doxorubicin-induced myocardial injury.
Topics: Antibiotics, Antineoplastic; Cardiomyopathies; Cardiovascular Agents; Disease-Free Survival; Doxorubicin; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Razoxane; Remission Induction | 2004 |
Gender-dependent reductions in vertebrae length, bone mineral density and content by doxorubicin are not reduced by dexrazoxane in young rats: effect on growth plate and intervertebral discs.
Topics: Age Factors; Animals; Antineoplastic Agents; Bone Density; Cardiovascular Agents; Densitometry; Doxorubicin; Female; Growth Plate; Intervertebral Disc; Male; Rats; Rats, Sprague-Dawley; Razoxane; Sex Characteristics; Tomography, X-Ray Computed | 2005 |
[Cardioxan: prevention of anthracycline-related cardiotoxicity].
Topics: Adolescent; Adult; Age Factors; Aged; Animals; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Lewis Lung; Cardiotonic Agents; Cardiovascular Agents; Chelating Agents; Child; Clinical Trials as Topic; Doxorubicin; Echocardiography; Electrocardiography; Female; Heart; Heart Diseases; Humans; Immunosuppressive Agents; Leukemia, Experimental; Male; Mice; Mice, Inbred C57BL; Neoplasms; Neoplasms, Experimental; Razoxane; Time Factors | 2004 |
The antitumor anthracyclines doxorubicin and daunorubicin do not inhibit cell growth through the formation of iron-mediated reactive oxygen species.
Topics: Animals; Anthracyclines; Antibiotics, Antineoplastic; Cardiovascular Agents; Cell Culture Techniques; Cell Proliferation; Daunorubicin; Doxorubicin; Enzyme Inhibitors; Iron; Models, Animal; Myocytes, Cardiac; Rats; Rats, Sprague-Dawley; Razoxane; Reactive Oxygen Species; Topoisomerase II Inhibitors | 2005 |
Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.
Topics: Anemia; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Cardiovascular Agents; Cell Culture Techniques; Colony-Forming Units Assay; Daunorubicin; Doxorubicin; Etoposide; Female; Leukopenia; Mice; Neutropenia; Razoxane; Thrombocytopenia | 2005 |
Amifostine and dexrazoxane enhance the rapid loss of bone mass and further deterioration of vertebrae architecture in female rats.
Topics: Amifostine; Animals; Antibiotics, Antineoplastic; Bone Density; Bone Resorption; Cardiovascular Agents; Doxorubicin; Drug Therapy, Combination; Female; Femur; Lumbar Vertebrae; Radiation-Protective Agents; Rats; Razoxane; Tomography, X-Ray Computed | 2005 |
Can dexrazoxane reduce myocardial injury in anthracycline-treated children with acute lymphoblastic leukemia?
Topics: Antibiotics, Antineoplastic; Cardiomyopathies; Cardiovascular Agents; Chelating Agents; Child; Clinical Trials as Topic; Disease-Free Survival; Doxorubicin; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Razoxane; Troponin T | 2004 |
Thrombopoietin protects against in vitro and in vivo cardiotoxicity induced by doxorubicin.
Topics: Animals; Antibiotics, Antineoplastic; Apoptosis; Blood Cell Count; Cardiomyopathies; Cardiovascular Agents; Cells, Cultured; Doxorubicin; Drug Evaluation, Preclinical; Heart Rate; Male; Mice; Mice, Inbred BALB C; Myoblasts; Myocytes, Cardiac; Proto-Oncogene Proteins c-akt; Rats; Razoxane; Reactive Oxygen Species; Single-Blind Method; Thrombopoietin; Ultrasonography | 2006 |
Prediction and prevention of chemotherapy-induced cardiomyopathy: can it be done?
Topics: Angiotensin-Converting Enzyme Inhibitors; Anthracyclines; Antineoplastic Agents; Cardiomyopathies; Cardiovascular Agents; Dose-Response Relationship, Drug; Heart; Humans; Predictive Value of Tests; Razoxane; Risk Factors; Stroke Volume | 2006 |
Subacute cardiotoxicity caused by anthracycline therapy in children: can dexrazoxane prevent this effect?
Topics: Acute Disease; Anthracyclines; Cardiomyopathy, Dilated; Cardiovascular Agents; Child; Female; Heart; Humans; Male; Razoxane; Risk Factors | 2007 |
Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats.
Topics: Animals; Antibiotics, Antineoplastic; Cardiomyopathies; Cardiovascular Agents; DNA, Mitochondrial; Doxorubicin; Electron Transport Complex IV; Energy Metabolism; Gene Expression; Male; Malondialdehyde; Mitochondria, Heart; Oxidative Phosphorylation; Rats; Rats, Wistar; Razoxane; Reactive Oxygen Species; Superoxides | 2007 |
Effects of dexrazoxane and amifostine on evolution of Doxorubicin cardiomyopathy in vivo.
Topics: Amifostine; Animals; Antibiotics, Antineoplastic; Cardiomyopathies; Cardiovascular Agents; Creatine Kinase; Doxorubicin; Female; Hydroxybutyrate Dehydrogenase; Mice; Mice, Inbred BALB C; Myocardium; Radiation-Protective Agents; Razoxane; Time Factors | 2007 |
Cardioprotective effect of dexrazoxane in patients with breast cancer treated with anthracyclines in adjuvant setting: a 10-year single institution experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiovascular Agents; Dose-Response Relationship, Drug; Doxorubicin; Electrocardiography; Epirubicin; Female; Follow-Up Studies; Heart Failure; Humans; Incidence; Life Expectancy; Middle Aged; Neoplasm Metastasis; Razoxane; Retrospective Studies | 2008 |
Dexrazoxane protects the heart from acute doxorubicin-induced QT prolongation: a key role for I(Ks).
Topics: Animals; Antibiotics, Antineoplastic; Aza Compounds; Cardiovascular Agents; Cell Line; Delayed Rectifier Potassium Channels; Dose-Response Relationship, Drug; Doxorubicin; Drug Evaluation, Preclinical; Ether-A-Go-Go Potassium Channels; Fluoroquinolones; Guinea Pigs; Humans; In Vitro Techniques; Inhibitory Concentration 50; Long QT Syndrome; Moxifloxacin; Quinolines; Razoxane | 2010 |
The effect of dexrazoxane for clinical and subclinical cardiotoxicity in children with acute myeloid leukemia.
Topics: Adolescent; Anthracyclines; Cardiovascular Agents; Child; Child, Preschool; Female; Follow-Up Studies; Heart Diseases; Humans; Infant; Leukemia, Myeloid, Acute; Male; Prospective Studies; Razoxane; Survival Rate; Treatment Outcome | 2010 |
Cardiac remodeling and MMPs on the model of chronic daunorubicin-induced cardiomyopathy in rabbits.
Topics: Animals; Antibiotics, Antineoplastic; Cardiomyopathies; Cardiovascular Agents; Chronic Disease; Collagen; Daunorubicin; Disease Models, Animal; Drug Interactions; Fibrosis; Hydroxyproline; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Myocardium; Rabbits; Razoxane; Ventricular Remodeling | 2010 |
Safety of concurrent administration of dexrazoxane and doxorubicin in the canine cancer patient.
Topics: Animals; Cardiovascular Agents; Dog Diseases; Dogs; Doxorubicin; Drug Therapy, Combination; Gastrointestinal Diseases; Heart Diseases; Neoplasms; Razoxane | 2010 |
Hydrophilic interaction liquid chromatography in the separation of a moderately lipophilic drug from its highly polar metabolites--the cardioprotectant dexrazoxane as a model case.
Topics: Cardiovascular Agents; Chromatography, Liquid; Ethylenediamines; Glycine; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Models, Chemical; Razoxane; Tandem Mass Spectrometry; Temperature | 2011 |
Drug may protect children's hearts from chemotherapy.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Cardiovascular Agents; Child; Doxorubicin; Female; Heart Diseases; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Randomized Controlled Trials as Topic; Razoxane; Sex Characteristics | 2010 |
Protective effects of dexrazoxane against acute ischaemia/reperfusion injury of rat hearts.
Topics: Acute Disease; Animals; Arrhythmias, Cardiac; Cardiovascular Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Electrocardiography; In Vitro Techniques; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Perfusion; Rats; Rats, Wistar; Razoxane; Reactive Oxygen Species; Treatment Outcome | 2012 |
Cardioprotective effect of early dexrazoxane use in anthracycline treated pediatric patients.
Topics: Adolescent; Age Factors; Anthracyclines; Cardiovascular Agents; Cardiovascular Diseases; Child; Child, Preschool; Female; Heart Function Tests; Hospitals, Teaching; Humans; Infant; Male; Neoplasms; Razoxane; Republic of Korea; Retrospective Studies | 2012 |
Development of LC-MS/MS method for the simultaneous analysis of the cardioprotective drug dexrazoxane and its metabolite ADR-925 in isolated cardiomyocytes and cell culture medium.
Topics: Animals; Animals, Newborn; Cardiovascular Agents; Cells, Cultured; Chromatography, Liquid; Ethylenediamines; Glycine; Myocytes, Cardiac; Pilot Projects; Rabbits; Rats; Rats, Wistar; Razoxane; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2013 |
Dexrazoxane prevents the development of the impaired cardiac phenotype in caveolin-1-disrupted mice.
Topics: Animals; Apoptosis; Atrial Natriuretic Factor; Cardiomyopathies; Cardiovascular Agents; Caveolin 1; Mice; Mice, Inbred C57BL; Mice, Knockout; Nitric Oxide Synthase; Phenotype; Razoxane; Reactive Oxygen Species; Treatment Outcome; Ventricular Function, Left | 2013 |